May 12 – Infraredx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery and other vascular diseases, today announced that its TVC Imaging System™ for the true vessel characterization of coronary artery disease will be featured in panels, live case presentations and a plenary session at EuroPCR 2012, being held May 15-18, 2012 at the Palais des Congrès in Paris.
The TVC Imaging System is a first-in-class intravascular imaging system with the unique ability to assess vessel composition and structure via integrated near infrared spectroscopy (NIRS) lipid core plaque (LCP) detection and enhanced intravascular ultrasound (IVUS) imaging technology. The TVC Imaging System is the only device available in both the U.S. and Europe for the detection of the LCPs known to complicate stinting and believed to be the reason for most heart attacks. Outside of the U.S., the TVC Imaging System is available in more than 30 countries worldwide.
“With more than two million people worldwide undergoing coronary stinting each year, there is a growing awareness of the clinical advantages of characterizing vessel structure and composition,” said Donald Southard, president and chief executive officer of Infraredx. "The TVC Imaging System integrates NIRS and IVUS technologies for true vessel characterization, which provides quick and valuable information for informed clinical decision-making. Since obtaining CE Mark approval and launching the TVC Imaging System in the European market a year ago, we have made significant progress in advancing our global commercialization strategy. We look forward to presenting the latest updates on our technology and discussing the clinical benefits that the TVC Imaging System provides in the diagnosis and management of coronary artery disease at EuroPCR 2012.”
About TVC Imaging System™
The TVC Imaging System™ is a first-in-class intravascular imaging system that holds the potential to revolutionize the management of coronary artery disease by providing information that is critical for evaluating vessel structure and composition, also known as true vessel characterization. The TVC Imaging System helps interventional cardiologists identify which patients are prone to complications during stinting. The TVC system enables cardiologists to predict peri-procedural heart attacks by assessing not only the degree of stenosis, but also the presence and extent of lipid core plaques (LCP) of interest.
In a single pullback, the TVC Imaging System provides rapid and automated detection of LCPs during the cardiac catheterization procedure. The device is the only multimodality imaging system to combine both intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS). Through IVUS technology, the TVC Imaging System provides clear and relevant information about vessel structure in real time. The system’s enhanced IVUS image provides a clear view of the vessel and plaque, providing more reliable vessel interpretation and assessment.
The system’s NIRS technology enables interventional cardiologists to reliably visualize the presence of LCP and predict the risk of peri-stenting myocardial infarction. The multimodality images are obtained simultaneously and require no post-processing or image manipulation. The TVC Imaging System is the only device approved by the U.S. Food and Drug Administration for the detection of LCP.
About Infraredx, Inc.
Infraredx, Inc. is a privately-funded medical device company dedicated to helping provide practitioners with the information needed for enhanced clinical decision making in treating coronary artery disease. The company is committed to improving the safety and efficacy of coronary stinting and ultimately serving as part of a strategy to prevent initial coronary events. Through its TVC Imaging System™, Infraredx is changing the way coronary artery disease is diagnosed and treated.
The TVC Imaging System is the only intravascular imaging system that enables true vessel characterization through simultaneous structural and compositional imaging data obtained in a single pullback. Through the use of both intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS) technologies, the system helps interventional cardiologists identify which patients are prone to stinting complications by assessing not only the degree of stenosis, but also the presence of lipid core plaque. Founded in 1998, Infraredx is headquartered in Burlington, Mass. For more information, visit www.infraredx.com.
Susan Heins (media)
Pure Communications, Inc.
Vice President of Marketing